Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Ensure aseptic handling when preparing the infusion.Remove both vials (each containing 2.5 g/50 mL idarucizumab) from carton.

There is limited data to support administration of an additional 5 g of Praxbind. Both vials are packaged together in one carton. The recommended dose of Praxbind is 5 g, provided as two separate vials each containing 2.5 g/50 mL idarucizumab (see Figure 1). In life-threatening or uncontrolled bleedingĢ DOSAGE AND ADMINISTRATION Recommended Dose.

For emergency surgery/urgent procedures.National Library of Medicine.Praxbind is indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed: ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Idarucizumab Archived at the Wayback Machine, American Medical Association.'International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 76'. 'International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71'. Food and Drug Administration (FDA) (Press release). ^ 'FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa'.

^ Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al.

^ a b c 'Praxbind- idarucizumab injection'.

^ 'Praxbind 2.5 g/50 mL solution for injection/infusion - Summary of Product Characteristics (SmPC)'.

^ 'Prescription medicines: registration of new chemical entities in Australia, 2016'.

Praxbind fda approval